Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD5 | P21918 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6152303 | 0.87 | HTR1A (0.53) | GPR119ACHEKDM4EPKMHTR1A | |
| SCHEMBL5475624 | 0.84 | ACHE (0.53) | GPR119ACHEKDM4EPKM | |
| SCHEMBL31596884 | 0.83 | GPR119 (0.53) | GPR119ACHEKDM4EPKM | |
| SCHEMBL6953531 | 0.82 | ACHE (0.55) | GPR119ACHEKDM4EPKM | |
| SCHEMBL31402474 | 0.80 | KDM4E (0.50) | GPR119ACHEKDM4EPKMDRD2 | |
| SCHEMBL22849386 | 0.80 | GPR119 (0.52) | GPR119NAMPT | |
| SCHEMBL21911480 | 0.79 | KDM4E (0.49) | GPR119KDM4EPKMNAMPT | |
| SCHEMBL30288086 | 0.79 | GPR119 (0.52) | GPR119ACHEKDM4EPKM | |
| SCHEMBL29890980 | 0.78 | ACHE (0.64) | GPR119ACHEKDM4EPKM | |
| SCHEMBL8825578 | 0.78 | ACHE (0.64) | GPR119ACHEKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | GPR119 2782/4885ACHE 3442/4885KDM4E 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.